(Reuters) - The new formulation provides bottle packaging and a new
12.5 mg dosage strength, in addition to 25 mg and 100 mg dosage
strengths, the company said in a statement.
FazaClo, which contributed $6.3 million to Avanir's sales
in the first quarter of 2007, is an orally disintegrating
formulation of clozapine for schizophrenic patients who fail to
respond adequately to standard drug treatments.
Read more at Reuters.com Government Filings News
12.5 mg dosage strength, in addition to 25 mg and 100 mg dosage
strengths, the company said in a statement.
FazaClo, which contributed $6.3 million to Avanir's sales
in the first quarter of 2007, is an orally disintegrating
formulation of clozapine for schizophrenic patients who fail to
respond adequately to standard drug treatments.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment